Bio-Techne (TECH) Q1 2026 Earnings Call Transcript

Image source: The Motley Fool.

Date

Nov. 5, 2025, 9:00 a.m. ET

Call participants

President and Chief Executive Officer — Kim Kelderman

Chief Financial Officer — James T. Hippel

Need a quote from a Motley Fool analyst? Email pr@fool.com

Risks

Organic revenue declined 1% due to clinical stage timing at key cell therapy customers and sustained softness in biotech funding, with CFO Hippel stating, "biotech funding remains down approximately 19% year to date through October."

Management expects cell therapy headwinds to intensify in Q2, projecting a 400-basis-point impact on growth, before moderating in the second half of the year.

Protein Sciences segment operating margin decreased 100 basis points to 38.4%, primarily from volume deleverage and promotional activity, partially offset by operational productivity.

Management cited "continued funding pressure in biotech" and "NIH budget uncertainty" as factors clouding demand visibility, noting, "the current government shutdown clouds visibility into the fiscal year 2026 budget."

Takeaways

Total revenue -- $286.6 million, down 1% year over year on both an organic and reported basis, with foreign exchange a 1% tailwind and businesses held for sale a 1% headwind.

Adjusted EPS -- $0.42, unchanged from prior year, and GAAP EPS $0.24, up from $0.21.

Adjusted operating margin -- 29.9%, representing a 90-basis-point improvement year over year, exceeding initial expectations.

Protein Sciences segment revenue -- $202.2 million reported, down 1% year over year, with organic revenue decline of 3% and operating margin of 38.4% (down 100 basis points).

Diagnostics and spatial biology segment revenue -- $79.5 million, down 4% as reported; organic growth 3% after adjusting for a 7% headwind from the Exosome Diagnostics divestiture, with operating margin up to 11.2% from 5.1%.

Cell therapy headwind -- CFO Hippel noted Q1 organic revenue would have been plus 1% excluding the timing impact from largest cell therapy customers who received FDA Fast Track designation; these customers caused a 200-basis-point headwind in Q1 and are expected to create a 400-basis-point headwind in Q2.

Geographical performance -- Revenue declined mid-single digits in the Americas, but EMEA and Asia each grew low single digits; China achieved a second consecutive quarter of growth.

Large pharma vs. biotech -- Revenue from large pharma customers increased low double digits, while biotech end markets declined high single digits.

ProteinSimple instrument franchise -- Cartridge consumable sales resumed double-digit growth and Simple Western (LEO) platform "exceeded both revenue and placement expectations" according to James T. Hippel in its first three quarters.

Spatial biology -- RNAscope suite grew low single digits; COMET instrument bookings increased double digits year over year; spatial biology was flat for the segment overall.

Operating cash flow -- $27.6 million for the quarter, with $5.4 million in net capital expenditures; year-over-year decline attributed to cash tax payment timing.

Shareholder returns and leverage -- $12.4 million returned in dividends; average diluted shares outstanding down 3% to 156.4 million, and leverage ratio well below 1x EBITDA.

Wilson Wolf acquisition path -- Bio-Techne currently owns 20%, expects to acquire remaining interest by 2027 or sooner if milestones are met, and Wilson Wolf’s trailing twelve-month growth sits at low- to mid-teens.

Sustainability milestone -- Achieved a 40% reduction in scope one and two emissions driven by transition to 100% renewable electricity at the largest site.

Summary

Bio-Techne (NASDAQ:TECH) reported a 1% year-over-year decline in total revenue to $286.6 million, reflecting challenges from clinical stage timing in cell therapy and continued weakness in biotech funding. Adjusted operating margin expanded by 90 basis points to 29.9%, driven by productivity and the Exosome Diagnostics divestiture, even as the Protein Sciences segment saw margin compression from volume deleverage and promotions. Management projects that headwinds from top cell therapy customers will intensify in Q2—impacting growth by 400 basis points—before easing in the second half as comparables improve. Strength in large pharma, renewed growth in China, and stabilization in academic markets were highlighted, supporting guidance for low single-digit organic growth for the full year despite near-term volatility.

Kelderman said, "we feel that the low single digits for the year is still very, very feasible" despite acknowledging short-term headwinds from cell therapy customers rewarded with FDA Fast Track designation.

Excluding largest cell therapy customers, management reported underlying organic growth of 1% in Q1, with guidance outlining an acceleration to approximately 3% in Q2 outside these accounts.

Diagnostic and spatial biology segment posted 3% organic growth after accounting for the Exosome Diagnostics divestiture, with noted double-digit growth in COMET bookings.

Operating cash flow declined year over year due to timing of tax payments, while returns to shareholders and a leverage ratio under 1x EBITDA were maintained.

The Wilson Wolf business was flat in the quarter, affected by broader biotech funding headwinds, but management remains confident in its longer-term prospects and acquisition timeline.

Industry glossary

GMP reagents: Good Manufacturing Practice–grade biologics used for cell therapy and clinical manufacturing, requiring rigorous quality standards.

Spatial biology: Techniques and platforms for analyzing distribution and interaction of biomolecules within tissue samples at high resolution.

RNA Scope: In situ hybridization technology enabling detection and visualization of RNA sequences within individual cells in tissue samples.

Cartridge consumable pull-through: Recurring revenue from single-use cartridges consumed by an instrument installed base, providing an indicator of customer engagement and utilization.

Phase III trials: Late-stage clinical trials to assess efficacy and safety of new therapies in larger patient populations prior to regulatory approval.

Fast Track designation: An FDA program intended to expedite review of drugs treating serious conditions, impacting timing of commercial demand for related reagents.

Exosome Diagnostics divestiture: Sale of Bio-Techne's exosome-based diagnostics business, affecting segment revenue and margin comparisons.

COMET instrument: Bio-Techne’s automated spatial biology platform with multi-omic capabilities for academic and biopharma research.

Scope one and two emissions: Scope 1 covers direct emissions from owned sources; Scope 2 involves indirect emissions from purchased electricity, heating, and cooling.

Full Conference Call Transcript

Kim Kelderman, President and Chief Executive Officer, and James T. Hippel, Chief Financial Officer of Bio-Techne. Before we begin, let me briefly cover our safe harbor statement. Some of the comments made during this conference call may be considered forward-looking statements, including beliefs and expectations about the company's future results. The company's 10-K for fiscal year 2025 identifies certain factors that could cause the company's actual results to differ materially from those projected in the forward-looking statements made during this call. The company does not undertake to update any forward-looking statements because of any new information or future events or developments.

The 10-K as well as the company's other SEC filings are available on the company's website within its Investor Relations section. During the call, non-GAAP financial measures may be used to provide information pertinent to ongoing business performance. Tables reconciling these measures to the most comparable GAAP measures are available in the company's press release issued earlier this morning on the Investor Relations section of our Bio-Techne Corporation website at www.techne.com. Separately, in the coming weeks, we will be participating in the UBS, Stifel, Stevens, Jefferies, Citi, Evercore, and Nasdaq Healthcare Conferences. We look forward to connecting with many of you at these upcoming events. I will now turn the call over to Kim.

Kim Kelderman: Thank you, Dave, and good morning, everyone. Welcome to Bio-Techne's first quarter earnings call for fiscal 2026. We began the fiscal year with continued strong execution, navigating a dynamic environment with discipline and strategic focus. Despite these efforts, organic revenue declined 1% in the quarter, primarily due to clinical stage timing from a couple of large customers in our cell therapy business and the anticipated ongoing softness in biotech funding. The headwinds in cell therapy reflect the inherent lumpiness of late-stage clinical programs, which in this case is driven by favorable FDA Fast Track designation that supports accelerated therapy approval timelines, yet they reduce near-term reagent demand.

Importantly, underlying market trends remain constructive as demand from our large pharma customers was once again robust, and we saw encouraging signs of stabilization in our US academic end market, particularly as the quarter progressed. Our ProteinSimple insulin franchise continued to build momentum, China delivered its second consecutive quarter of growth, and our spatial biology business assumed sequential improvement. Operationally, the team delivered sector-leading profitability with adjusted operating margin expanding 90 basis points year over year to 29.9%, exceeding our initial expectations. This performance reflects our deliberate focus on productivity and cost management while continuing to invest in the strategic growth pillars that will shape Bio-Techne's future.

Now let's turn to the performance of our end markets, beginning with our biopharma customers excluding cell therapy. The divergence between large pharma and emerging biotech spending patterns persisted in the first quarter. Revenue from our large pharma customers remained strong, increasing low double digits, reflecting continued demand for our tools and technologies. In contrast, the challenging funding environment in our biotech end market continued to weigh on spending behavior and resulted in high single-digit decline in Q1. Encouragingly, we are seeing early signs of stabilization in biotech activity levels.

These include an uptick in M&A activity, favorable pharma in-licensing trends, and the potential for lower interest rates, all of which support a more constructive outlook for investment levels in emerging biotech companies. Global academic markets remained stable overall in Q1. A modest decline in US academic business was offset by mid-single-digit growth in Europe, where demand trends remained healthy. Within the US, it was encouraging to see improvement in our run rate business as the quarter progressed. From a geographic standpoint, revenue declined mid-single digits in the Americas, while both EMEA and Asia delivered low single-digit growth.

James T. Hippel: In China, we achieved our second consecutive quarter of growth supported by improving CRO pipelines and increased CDMO activity. Growth in the region was primarily driven by strong performance in our ProteinSimple analytical instruments and our spatial biology portfolio. Importantly, unlike last quarter, the instrument growth does not appear to be driven by tariff-related dynamics. Instead, it reflects underlying demand strength, and we believe that the business is well-positioned for a return to stable growth in the region. Let's now turn to our growth pillars, beginning with the protein sciences segment where end market dynamics led to a 3% organic revenue decline.

In our cell therapy business, we were pleased to see a couple of our largest customers receive FDA Fast Track designation. This recognition enables an accelerated clinical development timeline and eligibility for priority review by the agency, potentially expediting both approval and commercialization of these next-generation therapies. As customers progress through the development project, they typically front-load purchases of the reagents needed for a full completion of the specific clinical phase in their program. We have seen this dynamic play out firsthand at Wilson Wolf, where customer ordering patterns moderated as their clients progressed through phase three clinical trials and shifted their focus to the regulatory filing necessary for FDA approval.

This is typically followed by an inflection in demand and a revenue ramp as therapies gain commercial traction. It is this clinical stage timing dynamic that introduced greater lumpiness in our cell therapy business in this quarter. Continuing with cell therapy, I'd like to provide a brief update on Wilson Wolf. As a reminder, we currently own 20% of the company and expect to complete the acquisition of the remaining interest by 2027 or potentially sooner, contingent upon the achievement of certain milestones. Wilson Wolf is a developer and manufacturer of the market-leading G-Rex bioreactor line, which enables high-yield, cost-effective workflows for cell therapy manufacturing.

The G-Rex also allows the scaling of production and, therefore, treats a greater number of patients efficiently. The G-Rex grant program has successfully seeded hundreds of early-stage cell therapy customers, and over half of those also utilize Bio-Techne's GMP reagents. We are very excited about the upcoming acquisition as the combination of Wilson Wolf's bioreactors and Bio-Techne's GMP reagents, ARMEDIA, and the pullback cytokine delivery system create a compelling lower-cost and scalable manufacturing solution for cell therapy developers. Let's now turn to a suite of easy-to-use, fully automated proteomic analytical solutions collectively known as ProteinSimple. These platforms are the preferred choice for fast, precise, and intuitive protein analysis.

Utilization of our expanding installed base remains very strong as customers increasingly rely on these systems to automate both critical and routine laboratory workflows, driving higher productivity in both biopharma and academia. This growing reliance was reflected in the cartridge consumable pull-through, which resumed its double-digit growth trajectory in the quarter. We continue to advance innovation across all three of our ProteinSimple instrument platforms, enhancing functionality, productivity, and broadening their application scope. A key highlight is the upcoming launch of an ultra-sensitive cartridge for our fully automated Simple Plex immunoassay platform branded as Ella. These next-generation assays will deliver a two to fivefold improvement in sensitivity of our current Simple Plex cartridge offering, enabling femtogram-level biomarker detection in plasma samples.

This breakthrough holds significant promise for accelerating neurodegenerative disease research and positions Bio-Techne as a leader in this emerging and impactful field. Adoption of our high-throughput Simple Western platform called LEO continues to build momentum with large pharma customers who value speed, simplicity, and sensitivity in protein quantification detection. We're very pleased with LEO's commercialization as the platform has exceeded both revenue and placement expectations in its first three quarters on the market. Combine this initial momentum with a growing order funnel, and LEO is well-positioned to become a standout performer in our instrument portfolio. Lastly, I'd like to highlight the continued success of our Maurice Biologics platform, which delivered its sixth consecutive quarter of growth.

This QA/QC solution is benefiting from a current wave of increased bioprocessing activity. Looking ahead, we see recent US investment announcements by several large pharmaceutical companies as a potential catalyst for accelerating growth in this business. And finally, our core portfolio of research-use-only reagents, including our industry-leading catalog of over 6,000 proteins and 400,000 antibody types, continues to demonstrate its enduring value to customers even amid challenging end market conditions. In the first quarter, sales of our core reagents remained in line with the prior year, underscoring the resilience and essential nature of these tools in supporting foundational research across disciplines. Now let's turn to our diagnostics and spatial biology segment. Beginning with our Spatial Biology portfolio.

In Q1, we delivered low single-digit growth in our RNAscope product suite, which enables biopharma and academic researchers to detect and visualize RNA and short microRNA sequences at a single-cell level within intact tissue samples. We will further strengthen our leadership in spatial biology with the launch of Proximity Scope, the first product to enable researchers to interrogate functional protein-protein interactions. This novel assay adds a powerful new dimension to multi-RNA and protein detection. By introducing this additional layer of information to spatial biology, Proximity Scope enhances researchers' ability to unravel complex biology and its connections to disease. It also embeds Bio-Techne's chemistry more deeply into automated translational research workflows.

Momentum also continued with our COMET instrument, as we saw solid double-digit growth in bookings year over year. Its fully automated, multi-omic capabilities are increasingly valued by academic and biopharma customers and enable the discovery of novel biological insights. Spatial biology continues to be our most academically concentrated business with a meaningful presence in biotech as well. Given the funding uncertainties in both end markets, we are encouraged by the positive momentum in this franchise. Lastly, our Diagnostics business grew mid-single digits in Q1, supported by balanced performance across our core diagnostic controls and our diagnostic kits for laboratories. We continue to see rising interest in our ESL1 test, which monitors resistance to standard therapies in breast cancer patients.

Recent clinical trial data reinforce the importance of testing for ESL1 mutations, showing that switching patients that show this mutation to an alternative therapy nearly doubled life expectancy compared to the standard treatment. We also launched the ImpreDEX PML-RARA kit, a multiplex qPCR assay designed to detect all three major fusion variants associated with APL, an aggressive form of leukemia. This assay runs on widely installed qPCR platforms and delivers results in approximately four hours. This launch broadens our hematology menu alongside the QuantiDEX PCR ABO kit and positions us for continued menu expansion. We also announced an expanded agreement with Oxford Nanopore Technologies, building on last year's successful launch of the Ampidex Nanopore Carrier Plus kit.

This comprehensive carrier screening panel targets 11 hard-to-sequence genes in a single workflow, offering laboratories a streamlined and efficient solution for genetic testing. Before I wrap up my prepared remarks, I would like to briefly highlight our progress on sustainability. During fiscal 2025, we achieved an estimated 40% reduction in scope one and two emissions driven by our transition to 100% renewable electricity at our largest site located in Minneapolis. I encourage everyone to review the report in the corporate and social responsibility section of our website. I'm proud of the team's continued progress on this front. To summarize, the Bio-Techne team continues to execute at a high level despite ongoing volatility across some of our end markets.

Our focus on productivity and disciplined cost management drove a significant year-over-year operating margin expansion, exceeding our expectations for profitability. While clinical stage timing in cell therapy created a headwind, underlying market trends are constructive. Recent data points suggest improving visibility for academic and our biopharma customers, which we expect will translate into stabilized and ultimately strengthening demand for life science tools, specifically Bio-Techne's product portfolio. One thing remains clear: our customers continue to rely on Bio-Techne's innovative life science tools to drive biological discovery, advance next-generation therapies, and deliver precise diagnostic solutions that improve the quality of life for the global population. With that, I'll turn the call over to Jim.

James T. Hippel: Thank you, Kim. I'll begin with additional detail on our Q1 financial performance followed by thoughts on our forward outlook. Adjusted EPS for the quarter was $0.42, flat year over year, with foreign exchange having an immaterial impact. GAAP EPS came in at $0.24, up from $0.21 in the prior year period. Total revenue for Q1 was $286.6 million, representing a 1% year-over-year decline on both an organic and reported basis. Foreign exchange contributed a 1% tailwind, while businesses held for sale created a 1% headwind. Excluding the timing impact from our largest cell therapy customers who received FDA Fast Track designation, organic growth was plus 1% for the quarter.

From a geographic lens, North America declined mid-single digits as strength from large pharma was offset by order timing in cell therapy and continued funding pressure in biotech. Europe grew low single digits led by consistent performance in academia, while Asia also posted low single-digit growth, marking its second consecutive quarter of sustained momentum. By end market, biopharma declined mid-single digits overall. However, excluding our largest cell therapy customers, biopharma grew low single digits, driven by strong pharma demand but partially offset by biotech softness. Academia was flat with solid growth in Europe, balancing modest declines in the US. Below the revenue line, adjusted gross margin was 70.2%, up from 69.5% last year.

The improvement was driven by the Exosome Diagnostics divestiture and ongoing productivity initiatives. Adjusted SG&A was 32.1% of revenue, nearly flat versus 32.2% last year. R&D expense was 8.2%, also stable compared to 8.3% in the prior year. This consistency reflects the benefits of structural streamlining and disciplined expense management, partially offset by targeted investments in strategic growth initiatives. Adjusted operating margin reached 29.9%, up 90 basis points year over year. This improvement was fueled by the Exosome Diagnostics divestiture and productivity gains, partially offset by volume deleverage. Our better-than-expected margin reflects deliberate management of productivity and cost containment measures aimed at maximizing operating leverage in a dynamic environment.

Below operating income, net interest expense was $1.8 million, up $700,000 year over year due to the expiration of interest rate hedges. Bank debt at quarter-end stood at $300 million, down $40 million sequentially. Other adjusted non-operating income was $2.7 million, down $1.3 million from the prior year, primarily due to foreign exchange gains last year related to overseas cash pooling arrangements that did not recur. Our adjusted effective tax rate was 22.3%, up 80 basis points year over year driven by geographic mix. Turning to cash flow and capital deployment, we generated $27.6 million in operating cash flow during our Q1 with $5.4 million in net capital expenditures.

The year-over-year decline in operating cash flow was due to the timing of cash tax payments. We returned $12.4 million to shareholders via dividends and ended the quarter with 156.4 million average diluted shares outstanding, down 3% year over year. Our balance sheet remains strong with $145 million in cash and a total leverage ratio well below one times EBITDA. M&A continues to be a top priority for capital allocation. Now let's review our segment performance, beginning with protein sciences. Q1 reported sales were $202.2 million, down 1% year over year. Organic revenue declined 3% with a 2% benefit from foreign exchange. Excluding the cell therapy timing impact, organic growth was plus 1%.

Growth was led by our proteomic analytical tools business, with notable strength from large pharma customers. Protein Sciences' operating margin was 38.4%, down 100 basis points year over year primarily due to volume deleverage and promotional activity, partially offset by operational productivity. In our diagnostics and spatial biology segment, Q1 sales were $79.5 million, down 4% year over year. The divestiture of Exosome Diagnostics negatively impacted reported growth by 7%, resulting in 3% organic growth for the segment. Diagnostics products grew mid-single digits while spatial biology was flat. It's worth noting that this segment grew mid-teens organically in the prior year, creating a challenging comparison.

Segment operating margin improved to 11.2%, up from 5.1% last year, driven by the Exosome Diagnostics divestiture and productivity initiatives. We expect continued margin expansion as our COMET spatial biology platform scales. In summary, the team delivered strong execution in Q1 despite persistent market headwinds, including biotech funding pressures, NIH budget uncertainty, and lingering tariff concerns. Encouragingly, recent data points suggest improving end market clarity. While biotech funding remains down approximately 19% year to date through October, industry reports show a 6% sequential increase in our Q1 and October making the strongest funding month of calendar 2025. Combined with recent large pharma pricing and onshoring agreements with the US administration, we anticipate improving conditions for biopharma.

On the NIH front, September outlays rose 8% year over year, closing the government's fiscal year on a strong note. While the current government shutdown clouds visibility into the fiscal year 2026 budget, both Senate and House appropriation bills suggest a flat NIH budget year over year. Encouragingly, we saw signs of stabilization in the US academic market as the quarter progressed. As Kim noted, we're excited about the FDA Fast Track designation award to our largest cell therapy customers. These designations accelerate clinical timelines but reduce near-term reagent demand. Following strong ordering in early fiscal year 2025, these customers are now progressing through their Phase III trials, resulting in a temporary slowdown in reagent purchases.

We expect this headwind to intensify in Q2, impacting growth by approximately 400 basis points year over year before moderating in the second half of the fiscal year. Despite these headwinds, we anticipate overall organic growth to be consistent with Q1. This outlook reflects continued strength in pharma, renewed growth in China, a rebound in spatial biology, and gradual stabilization in US academic and biotech end markets. As we lap prior year headwinds that began with the US administration's policy changes in early calendar 2025, we expect to return to positive organic growth in the second half of the fiscal year. From a margin perspective, we remain focused on balancing growth investments and operational efficiency.

We're pleased with the margin upside delivered in Q1 and remain on track to achieve at least 100 basis points of margin expansion for the full fiscal year. That concludes my prepared remarks. I'll turn the call now back over to the operator to open the line for questions.

Kim Kelderman: Thank you.

Operator: To leave the queue at any time, please press 2. Again, that is 1 to ask a question. As a reminder, please limit yourself to one question and a follow-up. We'll now pause for just a moment to allow everyone the chance to queue. Our first question will come from Dan Leonard with UBS. Your line is open.

Dan Leonard: Thank you very much and good morning. My first question, I appreciate all the quantification GMP protein timing dynamics, but what I'm curious about is how long might that air pocket persist? And how are you thinking about growth right now for GMP proteins in light of that? Greater than 30% growth in the prior year.

Kim Kelderman: Dan, thank you for the question, and good morning. Well, first of all, these two customers in particular, we're very excited about the fast track designation. It's obviously a very positive sign for these two customers and the therapies they're working on. But as you understand, short term, this gives us a headwind. And to be precise, this Q1, we saw a headwind of about 200 basis points based upon this phenomenon. It's on top of a prior year of 60% organic growth. For Q2, that will be worse. So Jim already mentioned 400 basis points, which would then lap a 90% prior year organic growth in cell therapy.

And from there, the second half of the year, the headwinds will fade. In the meantime, what we will continue to do is to build the funnel. Right now, we're sitting at 700 customers, 85 in clinical phases, 16 of those in phase two and five in phase three. And we are also very positive about the underlying recovery in the biotech markets. So yes, that will then result in us having to manage through this valley. I think we've positioned the company really well to continue to protect the bottom line, and we're very positive about all the other underlying strengths. So that's basically how we see the year rolling out.

Dan Leonard: Understood. Thank you for that. And my follow-up, Kim, are you still managing the business as a low single-digit grower in fiscal 2026? Or have those plans changed given the Q1 result and the upcoming comp you're facing here in Q2?

Kim Kelderman: No, not at all. No change there. As I mentioned, of course, the good news of these fast track approvals was somewhat of a short-term surprise for us, but our commitment and our conviction of cell therapy markets doing great over time remains exactly the same. And with some positive signs from the other end markets that we serve, we feel that the low single digits for the year is still very, very feasible. And as you saw from the Q1 margins, we've managed to protect the bottom line even with a bit of a headwind, we will always want to be on the safe side of that.

But in the meantime, we're ready for higher volumes in all the other product lines and for accelerating results.

Operator: Thank you. Our next question will come from Matthew Larew with William Blair. Your line is open.

Matthew Larew: Hi. Hi. Good morning. Maybe I'll just follow-up on that point there. Kim, you referenced the headwind accelerated, I think, to 400 bps in the fiscal second quarter. But still targeting low single digits for the business for the year. So it sounds like you are seeing an improvement in the underlying core, and I think that would suggest sort of mid-single-digit growth. The back half of the fiscal year, which may be consistent with what some of your peers have said, three to six. So can you maybe just speak to x CTX, how you see the balance that you're unfolding in light of the macro dynamics you referenced.

James T. Hippel: Yeah, Matt. Hi. This is Jim. Thanks for the question. I'll jump in on this one. So you are correct. I mean, we are the underlying business, we are seeing, I'd say, you know, a gradual improvement slash acceleration of our end markets and then our relative performance. So as I talked about, if you exclude just these two cell therapy customers, our organic growth would have been 1% for the company. Looking ahead to Q2, what really implies the guide implies is, you know, roughly a 3% growth. Ex these two customers. And that's before we get into the back half of the year where we start to lap the US administration policy changes that's impacted our entire industry.

Particularly academic. As well as you may remember, we talked about this last quarter, our diagnostics business in particular. Was you know, it can be lumpy from quarter to quarter. Had very last year was very, very strong in the first half. Little bit less so ordering in the second half. And that pattern is a bit flipped this year where we're expecting a stronger ordering pattern in the second half versus the first half. So, both the markets gradually improving, our specific product lines, namely our spatial, our ProteinSimple product line, and even the region in Asia overall, but especially China. Are all seeing some very nice positive momentum.

Combine that with, you know, lapping easier comps in the second half of the year, suggest a continued, you know, continued strength in, underlying performance absent these two customers.

Matthew Larew: Okay. Great. That's really helpful, Jim. And then you know, on the biotech side, you referenced sort of the variety of improving macro indicators and recently, of the nice news on biotech funding. You know, historically, you've thought about kind of a two to three-quarter lag there. I'm curious given how long we've sort of been in this, the doldrums, if you know, you expect that to be the same timeline or perhaps you've already started to see some signs of life some of your biotech customers who might feel better about the interest rate environment and their ability to raise capital.

Kim Kelderman: Yeah. Matt, I'll take it. Good morning. So we feel that biotech funding, as you referred to, over the last couple of months, has definitely increased. Specifically, the last month has been very, very positive. A lower interest rate environment also is helpful. Increased levels of M&A much higher than prior year. And then we also see a very encouraging number of licensing deals into biopharma, making it a more investable space, and therewith we feel positive about the momentum in there. Yes.

In the past, a couple of years ago, when we were looking at funding issues, we felt that the funding at that time came into companies that really had to start with brick and mortar, maybe clean rooms, and then work their way into starting their programs. Currently, in some occasions, that might still be the case, but we feel that overall infrastructure is in place and that many companies are fundraising to, you know, to kick their programs off and or to add some of the programs. And that will create an environment where the dollars probably will flow much quicker to us than the in the two, three quarters we've mentioned in the past.

Operator: Thank you. Our next question will come from Puneet Souda with Leerink Partners. Your line is open.

Puneet Souda: Yeah. Hi, Kim. I wanted to understand on the GMP protein side, could you talk about just knowing the number of trials that you're involved with, the ones that have fast track designation, and the ones that are program starts, can you maybe or clinical trial starts, maybe can you talk about are you see continuing to see the momentum on new clinical trial adds and for the same store customers that have fast track designation? I mean, when do you think just given the timing, ordering pattern, the size of the trials, can you give us a view into when this business starts to recover again for GMP proteins? Because, obviously, it's been a bright spot for you.

But just given the challenges, I wanted to understand when can that start to recover.

Kim Kelderman: Puneet, thank you for the question. Good morning. Yeah. The clinical starts have been relatively flat and steady, so we don't see a significant decline in the activity there. There's certainly some turnover there. New that are starting new clinical trials, and there are companies that are actually adding to their number of clinical trials. We've also seen some exits in cancellations. Basically, a maturing of the market where three, four years ago, basically, any novel technology or any novel treatment was getting funded, and some of those were basically more about how exciting these possibilities in cell therapy and gene therapy were versus the true viability if it comes to scalability as well as the affordability.

And we feel that all the new programs are much more in line with what cell and gene therapy is really, really fit for. And we actually, from Wilson Wolf as well as in Bio-Techne point of view, have always wanted to enable a scalable as well as an affordable treatment coming out of the cell and gene therapy effort. So we feel that we're really well positioned to continue to feed this end market.

Puneet Souda: Okay. That's helpful. And then if I could ask on the academic side, net, academic sentiment is improving. I appreciate that. But there is multiyear funding number of grants that are lower in 2026 versus 2025, more concentration, fewer grad students, fewer bodies in the lab, fewer postdocs. So how does that impact your business into '26 and beyond? And then when we look at the guide overall, Jim, you know, low single digit is lower than a large diversified peer in the space in life science tools. Just wondering, you know, historically, you've grown ahead of that peer by a few points. Is that still the assumption longer term?

And by that, I mean, you know, '26 and '27 eventually into '27. I mean, thank you.

Kim Kelderman: Yeah. I'll take the first part then, Puneet. So yes, we have seen stabilization in the NIH markets and specifically in academic US. Academic Europe has continued to grow mid-single digits. In the US, it's been a little lower, but definitely stabilizing, and we can see it from the overall activity level from our run rate, our core products. And then you know, we've always talked about how we feel that the number of NIH grants is important, but that they are aligned with our research areas the ones that we serve as a company, is more important. And we can clearly see a positive mix if it comes to these grants for us.

Then at the end of the day, we are encouraged by the fact that there's still bipartisan support for a flat NIH budget for the coming year. So we feel overall that this market has bottomed down, that is now stabilizing, and that it will be a positive driver for us going forward.

James T. Hippel: And then, Puneet, if I understood your question correctly, it kinda like, you know, how do I think about our performance relative to the space overall? And we've always talked about, you know, our level of outperformance, and do we expect that to continue going forward? And the answer is absolutely yes. I think what we're seeing right now is a bit of a transition, as you would expect when there's kind of a turn and trajectory of the business. You look at the peer sets, those obviously that have a more portfolio that's diversified outside even life sciences, but applied markets are accelerating, recovering earlier.

Those that have a higher bioprocessing presence are recovering earlier, which is actually a good sign downstream for eventually for discovery. You know, we peel back the onion and look at our very specific areas of where we play versus our competition. We feel like in you know, we're either holding our own or doing better. So for example, in our core reagents, globally, basically, we're setting at flat growth in our core reagents, which based off of our intel and our peer set, we're still doing as good if not taking share there. Our ProteinSimple franchise continues to do better than the market at mid-single-digit growth.

You know, our spatial biology franchise has been by their academic presence, but we've seen a turn of momentum there this most recent quarter. And we're seeing that momentum continue here in the second quarter. So we believe that will get back to the trajectory that we're used to seeing. And then, you know, cell therapy has been one of the reasons for our outperformance in the past. And gonna be a bit of a headwind for us in the coming quarters.

But once we lap those, and particularly once we get into fiscal year 2027, we'll be completely behind those tough comps with these two specific customers, and that will continue to be an accelerator of growth relative, we think, to our peers. So hopefully, that gives you enough detail to noodle on, but that's how we think about it.

Operator: Thank you. Our next question comes from Patrick Donnelly with Citi. Your line is open.

Patrick Donnelly: Hey, guys. Thank you for, thanks for taking the question. Maybe one on the Wilson Wolf piece. I'll always try to keep tabs on that. Can you just give an update as to what the quarter looked like there? What the momentum looks like? Is there potential for anything to trigger before, you know, the end of that in the timeline even if they don't hit some of those milestones, we'd love just a little more color on how you're thinking about that piece.

Kim Kelderman: Patrick, thank you for the question. Yes. Wilson Wolf had a flat quarter, also looking at some of the biotech headwinds from the past couple of quarters from a funding perspective. Overall, the twelve-month trailing sits at mid-teens, low to mid-teens, and, yeah, we feel that overall that business is also very well positioned to accelerate again to their entitled growth rates. And yeah, we feel that will be a great acquisition serving the cell therapy market. The question regarding the triggers, whether we would be able to own it earlier. I bet that John Wilson will still think that he will be able to meet the EBITDA triggers, but, you know, we're supportive of course.

But the current market conditions and some of the headwinds, it will be a little tougher, which for us, basically, doesn't make a huge difference because the deal is structured in a way and you know how it is structured, that, at the end of the day, we would pay 4.4 times twelve months trailing revenues. And then we'll calculate the purchase price. And we're rooting for the team, and we see that they have plenty of pipeline to be proud of.

Operator: Thank you. Our next question will come from Daniel Arias with Stifel. Your line is open.

Daniel Arias: Jim, apologies for going back on the same question that was asked about 2Q, but I just wanna make sure I understand the cadence here. Because it sounds like you feel like demand has troughed and it's on its way back, and now it's really kinda just about rounding the corner on growth itself. So plus 1% organic this quarter, ex the GMP customers, and you're expecting the same thing next quarter ex those accounts, 3% without them. So 1% with them presumably. Despite the comp being five points more difficult.

So like, the underlying momentum that you guys are talking about basically feels like it can drive 500 basis points or so of sequential improvement in the context of the compares, excluding these two accounts, obviously.

James T. Hippel: Yeah. So let me just make I'll repeat my what I said my comments to make sure I'm clear. So yeah. So you're correct that in this current quarter, we just passed Q1, adjusted for these two customers of cell therapy out of our numbers. We would have grown 1% overall. And looking to at Q2, these same two customers provide a 400 basis points headwind, but we're projecting the same overall growth that we had in Q1. So that would imply that the underlying business outside of these two customers accelerates to 3% organic growth from the 1% we had this quarter.

Daniel Arias: I see. Okay. Okay. And then can you just maybe refresh us on what kind of eighty-twenty type rule exists when it comes to these cell therapy accounts? I mean, there's obviously a concentration here.

Kim Kelderman: Become larger. And then at the end of the day, the size of each account is, of course, also predicated on how many clinical study subjects do one need to. Because an account with a big indication and a large amount of proteins, in a phase two could be ordering more than a phase three for a specific disease. Exotic disease. So therefore, it's hard to answer a question. Overall, we always look at the total pipeline, made some real progress in adding customers to our pipeline, and we're sitting at 700 now. So overall, we are very confident we're driving the underlying growth and that we're participating in the market in a real significant way.

Operator: Thank you. Our next question will come from Kyle Boucher with TD Cowen.

Kyle Boucher: Hey, good morning guys. Thanks for taking the questions. I wanted to ask on the spatial side of the business. It sounds like pretty decent sequential growth there and trends sort of improved. Know you had some headwinds in the fiscal fourth quarter. Was there any catch up in fiscal Q1 from some of those disruptions you saw at the end of the last fiscal year?

Kim Kelderman: No. We don't believe that there is a catch up there. We truly see overall broad recovery in the ACD reagents, the RNAscope, we made it back into the black, which is really encouraging to see. And as I mentioned, real broad recovery, and then the instruments, yeah, they have a little bit of a tougher time like other instruments in relation to the academic side of the market. We have a real nice momentum that we saw in the order book. So, overall, we know that the reagents have been improving sequentially, not based upon lumpiness or quarterly order timing, but more just by broad activity level.

And the instrument funnel is growing really, really nicely looking at our order book.

Kyle Boucher: Got it. Thank you. And then maybe on the margin side, you know, came in pretty good in the fiscal first quarter, considering the minus 1% organic. But I guess next quarter assuming the same level of growth, you know, minus 1%. What does that sort of imply for the EBIT margin fiscal second quarter?

James T. Hippel: Well, we haven't given specific guidance on margin by quarter, but, you know, we got, you know, it's seen, you know, as the quarter progressed and we realized we're gonna have these headwinds with these two specific customers, you know, GMP Pro of course, are a very profitable part of our business. We've made sure we've taken even additional productivity actions to counter those, which allowed us to get the we got this quarter, but more importantly, prepare us for the headwinds yet to come, especially in Q2. So, you know, it gives us even more confidence in our ability to achieve our 100 basis point expansion goal for the year. And maybe even do a little bit better.

But, you know, obviously, how the top line plays out will have a lot of determination as to whether there's ups or downsides of that figure in any given quarter. But right now, we're feeling good about margin overall. Each and every quarter.

Operator: Thank you. Our next question will come from Catherine Schulte with Baird. Your line is open.

Catherine Schulte: Maybe first for the fiscal second quarter outlook, what does that assume for a government shutdown impact? And you maybe talk through the range of outcomes if, you know, we get a reopening tomorrow, versus a month from now.

James T. Hippel: Hey. This is Jim. I'll just start by saying that, you know, we're in that we're obviously in more record territory already with the government shutdown. And we haven't seen any noticeable major differences in our academic customer buying patterns, like this month versus the prior month. So, again, we're encouraged that academic has appeared to have stabilized over the past quarter. And we're seeing that continue thus far even with the academic shutdown. Or even with the government shutdown. Sorry.

Catherine Schulte: Okay. Helpful. And then on the GMP headwinds, you know, what are your assumptions for the back half of the year? I know they should ease. Is the easing of those due to them annualizing, or are you assuming some of that ordering resumes?

James T. Hippel: It's really more about how much they ordered in the first half of last year, these two customers, versus the second half. And they ordered less in the second half than in the first, there still will be a headwind. It should be it will definitely be less than what we saw in Q2. We'll give you, you know, give you more ideas as to the quarter approaches in terms of what we're seeing from these two customers, this time next quarter. But as of right now, we're not assuming much of any buying. For these two programs. And, you know, it's still a headwind in the second half, but not as severe.

Kim Kelderman: Thank you. Yeah. The comparables become easier. Right? Comparables become easier, Catherine. And in the meantime, you know, these companies also need to start validating processes and their manufacturing. So we feel that the second half will be less by this phenomenon than the first.

Operator: Our next question will come from Justin Bowers with Deutsche Bank. Your line is open.

Justin Bowers: Hi, good morning everyone. So in the prepared remarks you talked about instruments that could benefit from the onshoring and reshoring dynamic. Can you point to which cohort of instruments across the portfolio that might be the beneficiary biggest beneficiaries of this? And, you know, potential timing of when we'd like to see some benefit from that.

Kim Kelderman: Yes. Thanks for the question. In particular, are thinking about our Biologics Instrument Line. It's been growing really nicely compared to market. And we feel it's taking market share in several applications that it serves. And as you can imagine, with onshoring with more locations companies typically will utilize similar instrumentation and methods as they would did in their primary location. So we feel that we can copy our successes that we've booked in Europe and in the past in this particular end market in large pharma, and that will translate to some momentum going forward. Thank you.

Operator: Thank you. Our next question will come from Daniel Markowitz with Evercore ISI. Your line is open.

Daniel Markowitz: I have a couple quick ones. So first on cell therapy customer order timing, I just wanna make sure I understand the driver here correctly. I'm sorry for asking another question on this. Have these customers who received FCA Fast Track already placed orders for their phase three clinical trials and you've already recognized revenues for those phase three projects? And now you're just waiting for them to do commercial. I just wanna make sure I'm understanding that right.

Kim Kelderman: Yeah. Thanks for your question. Don't apologize. I mean, it's obviously a real result driver for this quarter specifically. Now the fast track designation, yes, after your initial results, in this case in these cases, while in phase two, the fast track designation would give you a whole pass to accelerate your clinical studies, and we feel that these customers and, of course, there's always a firewall, but we feel that you customers have ordered enough to finalize their clinical trials, and that's not uncommon. Typically, you buy your raw materials in quantities to make sure you don't have to deal with a new lot of raw materials during your clinical trials.

So yes, the materials for their Phase three for what they have to do would already in our assumptions, have ordered last year. And the materials that you would need for commercialization and for validation of your production lines, we feel is still to come.

Daniel Markowitz: Understood. That's helpful. Thank you. And then the second one, you mentioned promotional activity in protein sciences when talking about the margins there. Can you talk about these activities? Where were they focused? And would you expect them to continue in the coming quarters? And then I just had one more quick question at the end.

James T. Hippel: Yeah. I'll try to take this. This is, Jim. So the promotional activity thing, as you imagine, you know, we all know the academic environment is tough right now. Biotech environment has been tough. And, and so therefore, you know, you wanna make sure that you stick with your customers in good times and bad. And so that means, you know, perhaps that's a little bit heavier discounting, promoting certain product lines, helping with, you know, with their solutions. So it's really more about supporting our academic and biotech customers as they, you know, go through a tough time right now.

And so those additional promotional activities, I think, you know, helped our absolute performance relative to those markets as well. So at the end of the day, it paid off.

Kim Kelderman: Yeah. And if I add to that, you know, our grant as well as some promotions to get into projects early on, even in tough times. From the story that we just went through, you could clearly identify that being in a project or in the and driving the funnel of companies and or projects that are using in materials is very important. So in constrained markets, we wanna make sure we build the funnel and actually double down on all the projects that are currently going on. They're obviously very viable and important because they're still getting invested in.

So being part of those is of the utmost importance to make sure that you can continue to accelerate and outperform the rest of the market that's exactly what we're doing.

Daniel Markowitz: Okay. And then my last one, it's impressive you were able to deliver on margins and EPS despite the customer timing in a very high margin business. I'm curious if there was anything you wanted to call out that helped flex the business to make that happen. One thought that came to mind is maybe once you had less XO DX reinvestments and you let more of it drop down to the bottom line? And then what's expected for the balance of the year? Anything you wanted to call out on that front?

James T. Hippel: I mean, yes. So, you know, as we talked about, you know, we continue to want to balance our cost initiatives and productivity initiatives with reinvest back into our growth drivers. And, you know, it's a level we have to work with. And so you know, it's a combination, I'd say, of the timing of some of those investments. Perhaps pushing them out to later in the year in some cases. Also accelerating on the productivity front. So we initiated some new streamlining activities this quarter. Which bolstered our, you know, our efficiencies. And will set us up, you know, to be able to continue that margin performance even, with these new headwinds that we're facing here.

With the cell therapy.

Operator: Thank you. That brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.

James T. Hippel: To be honest, Kim, I don't know how many people hang out for that.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.